Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by Zacks Investment Research

Abeona Therapeutics (NASDAQ:ABEO – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm currently has a $0.25 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside […]

Related Keywords

United States ,Dallas ,Texas , ,Plasmatech Biopharmaceuticals Inc ,Virtu Financial ,Zacks Investment Research ,Nasdaq ,Capital Management ,Abeona Therapeutics Inc ,Citadel Advisors ,Citigroup Inc ,Abeona Therapeutics ,Get Rating ,Investment Research ,Therapeutics Inc ,Plasmatech Biopharmaceuticals ,Nasdaq Abeo ,Labeo ,Medical ,Upgrade ,